Tag: pharmaceuticals
-
Safer Forms of Psilocybin Assessed in Preclinical Study
A biotechnology company says it identified engineered precursors of a psychedelic compound that in lab animals produce safe and intended therapeutic effects.
-
$60M Challenge Seeks Biomarkers, Models to Counter Aging Stress
A new challenge competition seeks biomarkers, models, and clinical tests of the factors behind responses to stress conditions in human aging that can stave off frailty or death.
-
Measles-Rubella Patch Vaccine Shown Effective as Injection
A clinical trial shows a peel-and-stick patch device is as effective as a standard syringe injection in delivering a vaccine that protects against measles and rubella.
-
Biotech, Janssen Partner on Ultrasound for Gene Therapy
A developer of ultrasound bubbles to assist gene therapies is studying use of the technology with Janssen Pharmaceuticals for delivering DNA and RNA treatments.
-
Collaboration to Boost Rare Disease Clinical Trials
An organization seeking new uses for today’s drugs and a contract research company aim to increase the number of clinical trials for rare diseases testing already approved drugs.
-
Computational Drug Discovery Company Acquires A.I. Businesses
Two companies using artificial intelligence to advance biotechnology and design new therapies are merging with a computational-engineering drug discovery enterprise.
-
Infographic – Psychedelics Funding Coming Down
Technology intelligence company CB Insights says this week that psychedelic therapies and services are generating little interest among venture investors this year, with only nine deals totaling $21 million.
-
Crispr Therapy Shown to Remove E. Coli in Gut
New research with lab animals shows gene-edited viruses can target and remove harmful E. coli bacteria from the gut, including strains usually resistant to antibiotics.
-
Trial Underway Testing Psychedelic Drug for Depression
The first participant in a clinical trial received a dose of a psychedelic therapy, assessing the experimental compound in people with treatment resistant depression.
-
Biotech to Design Disease-Blocking Drugs, Gains $75M
A new company that says it can stop disease-causing proteins from forming in cells began public operations today, and is raising $75 million in its first venture round.